UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2197-11
Program Prior Authorization/Medical Necessity
Medication Enbrel® (etanercept)
P&T Approval Date 5/2020, 11/2020, 6/2021, 9/2021, 12/2021, 3/2022, 6/2022, 11/2022,
7/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Enbrel (etanercept) is a tumor necrosis factor (TNF) blocker indicated for the treatment of
rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years
of age or older, psoriatic arthritis (PsA) in patients 2 years of age or older, ankylosing
spondylitis (AS), and plaque psoriasis (PsO) in patients 4 years or older.
2. Coverage Criteriaa:
A. Rheumatoid Arthritis (RA)
1. Initial Authorization
a. Enbrel will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active rheumatoid arthritis
-AND-
(2) One of the following:
(a) History of failure to a 3 month trial of one non-biologic disease modifying
anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide,
sulfasalazine, hydroxychloroquine] at maximally indicated doses, unless
contraindicated or clinically significant adverse effects are experienced
(document drug, date, and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of rheumatoid arthritis as documented by claims
history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi
(golimumab), Olumiant (baricitinib), Rinvoq (upadacitinib),
Xeljanz/Xeljanz XR (tofacitinib)]
-OR-
(c) Both of the following:
© 2024 UnitedHealthcare Services, Inc.
1
i. Patient is currently on Enbrel therapy as documented by claims history or
submission of medical records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from the Amgen sponsored
Enbrel Support program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Enbrel*
-AND-
(3) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
-AND-
(4) Prescribed by or in consultation with a rheumatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from the Amgen sponsored Enbrel Support program shall be
required to meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Enbrel will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Enbrel therapy
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
B. Polyarticular Juvenile Idiopathic Arthritis (PJIA)
1. Initial Authorization
a. Enbrel will be approved based on all of the following criteria:
© 2024 UnitedHealthcare Services, Inc.
2
(1) Diagnosis of moderately to severely active polyarticular juvenile idiopathic
arthritis
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
-AND-
(3) Prescribed by or in consultation with a rheumatologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Enbrel will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Enbrel therapy
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
C. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Enbrel will be approved based on all of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) One of the following:
(a) History of failure to a 3 month trial of methotrexate at maximally indicated
dose, unless contraindicated or clinically significant adverse effects are
experienced (document date and duration of trial)b
-OR-
© 2024 UnitedHealthcare Services, Inc.
3
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of psoriatic arthritis as documented by claims
history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi
(golimumab), Stelara (ustekinumab), Tremfya (guselkumab),
Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi
(risankizumab), Rinvoq (upadacitinib)]
-OR-
(c) Both of the following:
i. Patient is currently on Enbrel therapy as documented by claims history or
submission of medical records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from the Amgen sponsored
Enbrel Support program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Enbrel*
-AND-
(3) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
-AND-
(4) Prescribed by or in consultation with one of the following:
(a) Rheumatologist
(b) Dermatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from the Amgen sponsored Enbrel Support program shall be
required to meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Enbrel will be approved based on both of the following criteria:
© 2024 UnitedHealthcare Services, Inc.
4
(1) Documentation of positive clinical response to Enbrel therapy
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
D. Plaque Psoriasis
1. Initial Authorization
a. Enbrel will be approved based on all of the following criteria:
(1) Diagnosis of chronic moderate to severe plaque psoriasis
-AND-
(2) One of the following:
(a) All of the following:
i. Greater than or equal to 3% body surface area involvement,
palmoplantar, facial, genital involvement, or severe scalp psoriasis
-AND-
ii. History of failure to one of the following topical therapies, unless
contraindicated or clinically significant adverse effects are experienced
(document drug, date, and duration of trial):
a. Corticosteroids (e.g., betamethasone, clobetasol, desonide)
b. Vitamin D analogs (e.g., calcitriol, calcipotriene)
c. Tazarotene
d. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
e. Anthralin
f. Coal tar
-AND-
iii. History of failure to of a 3 month trial of methotrexate at maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document date and duration of trial)b
-OR-
© 2024 UnitedHealthcare Services, Inc.
5
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of plaque psoriasis as documented by claims
history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla
(apremilast), Skyrizi (risankizumab), Stelara (ustekinumab), Tremfya
(guselkumab)]
-OR-
(c) Both of the following:
i. Patient is currently on Enbrel therapy as documented by claims history or
submission of medical records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from the Amgen sponsored
Enbrel Support program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Enbrel*
-AND-
(3) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
-AND-
(4) Prescribed by or in consultation with a dermatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from the Amgen sponsored Enbrel Support program shall be
required to meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Enbrel will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Enbrel therapy
© 2024 UnitedHealthcare Services, Inc.
6
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
E. Ankylosing Spondylitis (AS)
1. Initial Authorization
a. Enbrel will be approved based on all of the following criteria:
(1) Diagnosis of active ankylosing spondylitis
-AND-
(2) One of the following:
(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally
indicated doses, each used for at least 4 weeks, unless contraindicated or
clinically significant adverse effects are experienced (document drug, date,
and duration of trials)
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of ankylosing spondylitis as documented by
claims history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., adalimumab, Simponi (golimumab)]
-OR-
(c) Both of the following:
i. Patient is currently on Enbrel therapy as documented by claims history or
submission of medical records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from the Amgen sponsored
Enbrel Support program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Enbrel*
© 2024 UnitedHealthcare Services, Inc.
7
-AND-
(3) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
-AND-
(4) Prescribed by or in consultation with a rheumatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from the Amgen sponsored Enbrel Support program shall be
required to meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Enbrel will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Enbrel therapy
-AND-
(2) Patient is not receiving Enbrel in combination with another targeted
immunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation.; October 2023.
© 2024 UnitedHealthcare Services, Inc.
8
2. Ward MM, Deodhar, A, Gensler, LS, et al. 2019 Update of the American College of
Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment
Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic
Axial Spondyloarthritis. Arthritis & Rheumatology. 2019; 71(10): 1599-1613.
3. Yu, DT, van Tubergen A. Treatment of axial spondyloarthritis (ankylosing spondylitis and
nonradiographic axial spondyloarthritis) in adults. Sieper, J (Ed). UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com (Accessed on October 10, 2019.)
4. Singh, JA, Guyatt, G, et al. 2018 American College of Rheumatology/National Psoriasis
Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis & Rheumatology. 2019;
71(1): 5-32.
5. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of
psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.
6. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an
emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.
7. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis
with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.
8. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and
photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.
9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with
traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.
10. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update
2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol
2015;29:2277-94.
11. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for
the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment
of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J
Am Acad Dermatol. 2011 Jul;65(1):137-74.
12. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for the
management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis
2016;75:499-510.
13. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management
and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.
Program Prior Authorization/Medical Necessity - Enbrel (etanercept)
Change Control
5/2020 New program
6/2020 Administrative change. Updated formatting numbers for psoriatic
arthritis section with no change to clinical intent.
11/2020 Revised step therapy medications for psoriatic arthritis and psoriasis
due to expanded indications. Removed continuation of therapy
allowance.
6/2021 Removed prescriber requirement from reauthorization criteria. Added
coverage criteria for patients previously treated with a biologic
DMARD.
© 2024 UnitedHealthcare Services, Inc.
9
9/2021 Revised step requirements for rheumatoid arthritis, psoriatic arthritis,
plaque psoriasis, and ankylosing spondylitis. Updated background and
references.
12/2021 Updated the following with no change to clinical intent: updated
conventional DMARD bypass language for rheumatoid arthritis,
psoriatic arthritis and psoriasis, removed “biologic” from required
preferred product criteria language, updated age requirement language
and updated CT/KY footnote.
3/2022 Added Skyrizi as a preferred drug for active psoriatic arthritis.
6/2022 Added Rinvoq and Xeljanz as step therapy options for ankylosing
spondylitis and psoriatic arthritis.
11/2022 Removed step requirement through preferred products and added
continutation of therapy for RA, PsA, PsO, and AS.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
10/2024 Annual review with no change to coverage criteria. Updated
background, state mandate footnote, and reference.
© 2024 UnitedHealthcare Services, Inc.
10